Skip to Main Content

Paper Details

Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia.
Clin Cancer Res
9
2023
Author NameAffiliation
Mark J LevisJohns Hopkins Sidney Kimmel Comprehensive Cancer Center
Mark J LevisJohns Hopkins Sidney Kimmel Comprehensive Cancer Center
Areej El-JawahriMassachusetts General Hospital Cancer Center, Harvard Medical School
  • 1 - 3

Datasets

Release 1.2